Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHARLES PLIMPTON

Allopathic & Osteopathic Physicians Obstetrics & Gynecology

NPI
1891777835
CMS profile
267685
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$3,037.66

8 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $2,296.55 6
Food and Beverage $741.11 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
PFIZER INC. $3,037.66 8

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHARLES PLIMPTON

NPI 1891777835 · CMS profile ID 267685

Allopathic & Osteopathic Physicians / Obstetrics & Gynecology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
CHARLES PLIMPTON, NPI 1891777835, CMS profile ID 267685, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–8 of 8 matching records. This page contains 8 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1891777835?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

8 matching records · $3,037.66 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 8 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–8 of 8.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $578.4611/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673851687 CMS
PFIZER INC. $389.3511/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673852271 CMS
PFIZER INC. $314.1911/01/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673852273 CMS
PFIZER INC. $86.4011/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673852275 CMS
PFIZER INC. $467.2207/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030491 CMS
PFIZER INC. $130.4307/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030499 CMS
PFIZER INC. $654.7107/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030505 CMS
PFIZER INC. $416.9007/26/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673030511 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $3,037.66 8
PY2020 $4,550.00 1
PY2024 $164.80 3
PY2025 $63.56 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $280,140.77 30
PY2024 Principal investigator $631,342.46 58
PY2023 Principal investigator $604,319.86 129
PY2022 Principal investigator $1,688,412.68 133
PY2021 Principal investigator $3,601,852.60 159
PY2020 Principal investigator $853,852.30 65
PY2019 Principal investigator $195,210.58 10

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

129 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Merck Sharp & Dohme LLC $28,443.08 12/31/2023 Non-covered Recipient Entity
Velocity Clinical Research, Phoenix
A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety,Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Riskof Pneumococcal Disease No dispute reported 06/30/2026 1042488993
Principal investigator 1 ModernaTX, Inc. $104.00 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1040222247
Principal investigator 1 ModernaTX, Inc. $9,600.00 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 No dispute reported 06/30/2026 1040222347
Principal investigator 1 ModernaTX, Inc. $1,823.90 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 No dispute reported 06/30/2026 1040222373
Principal investigator 1 ModernaTX, Inc. $50.54 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 No dispute reported 06/30/2026 1040222385
Principal investigator 1 ModernaTX, Inc. $750.26 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 No dispute reported 06/30/2026 1040222399
Principal investigator 1 ModernaTX, Inc. $1,051.70 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 No dispute reported 06/30/2026 1040222411
Principal investigator 1 ModernaTX, Inc. $6,708.00 12/22/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS CoV-2 No dispute reported 06/30/2026 1040222493
Principal investigator 1 ModernaTX, Inc. $1,495.59 12/22/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002963
Principal investigator 1 PFIZER INC. $2,227.50 12/22/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1046381609
Principal investigator 1 ModernaTX, Inc. $598.00 12/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1040220967
Principal investigator 1 ModernaTX, Inc. $877.50 12/06/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Randomized, Observer-Blind, Placebo-Controlled, Age De-escalation, Dose-escalation Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Children 6 months to <12 years of age. No dispute reported 06/30/2026 1040221361
Principal investigator 1 PFIZER INC. $1,161.60 11/23/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045872977
Principal investigator 1 GlaxoSmithKline, LLC. $900.00 11/21/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789714
Principal investigator 1 ModernaTX, Inc. $1,470.88 11/17/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002897
Principal investigator 1 Organon LLC $249.00 11/17/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090965
Principal investigator 1 Organon LLC $152.00 11/17/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016123899
Principal investigator 1 ModernaTX, Inc. $39.00 11/10/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002891
Principal investigator 1 ModernaTX, Inc. $1,500.00 11/08/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002265
Principal investigator 1 Organon LLC $152.00 11/03/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016127975
Principal investigator 1 GlaxoSmithKline, LLC. $75.00 11/02/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789712
Principal investigator 1 GlaxoSmithKline, LLC. $225.00 11/02/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789716
Principal investigator 1 ModernaTX, Inc. $780.00 10/27/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002773
Principal investigator 1 ModernaTX, Inc. $750.00 10/27/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002785
Principal investigator 1 GlaxoSmithKline, LLC. $400.00 10/26/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED, OBSERVER-BLIND, MULTI-COUNT No dispute reported 06/30/2026 1127789706
Principal investigator 1 ModernaTX, Inc. $1,105.33 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002791
Principal investigator 1 Organon LLC $1,910.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090163
Principal investigator 1 Organon LLC $885.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090173
Principal investigator 1 Organon LLC $885.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090183
Principal investigator 1 Organon LLC $885.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090193
Principal investigator 1 Organon LLC $885.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090203
Principal investigator 1 Organon LLC $1,910.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090215
Principal investigator 1 Organon LLC $1,910.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090225
Principal investigator 1 Organon LLC $885.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090235
Principal investigator 1 Organon LLC $712.00 10/25/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016090245
Principal investigator 1 PFIZER INC. $2,323.20 10/25/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045870733
Principal investigator 1 PFIZER INC. $3,484.80 10/18/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045870745
Principal investigator 1 GlaxoSmithKline, LLC. $300.00 10/17/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 1006243551
Principal investigator 1 GlaxoSmithKline, LLC. $6,000.00 10/17/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 1006243557
Principal investigator 1 ModernaTX, Inc. $85.00 10/13/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002191
Principal investigator 1 ModernaTX, Inc. $209.95 10/13/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002779
Principal investigator 1 GlaxoSmithKline, LLC. $281.16 10/12/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789704
Principal investigator 1 ModernaTX, Inc. $1,100.38 09/27/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002767
Principal investigator 1 PFIZER INC. $1,161.60 09/23/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045865827
Principal investigator 1 ModernaTX, Inc. $12,528.75 09/20/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002711
Principal investigator 1 Organon LLC $7,416.00 09/20/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016080553
Principal investigator 1 ModernaTX, Inc. $8,684.00 09/13/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002705
Principal investigator 1 ModernaTX, Inc. $1,000.00 09/01/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002165
Principal investigator 1 ModernaTX, Inc. $1,500.00 09/01/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002171
Principal investigator 1 ModernaTX, Inc. $1,300.00 09/01/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002717
Principal investigator 1 Organon LLC $1,000.00 08/28/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016087753
Principal investigator 1 Organon LLC $750.00 08/28/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016087763
Principal investigator 1 Organon LLC $550.00 08/28/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016087773
Principal investigator 1 Organon LLC $1,000.00 08/28/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016087785
Principal investigator 1 ModernaTX, Inc. $955.50 08/25/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040215863
Principal investigator 1 PFIZER INC. $7,900.00 08/25/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1046422333
Principal investigator 1 PFIZER INC. $1,161.60 08/24/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045913435
Principal investigator 1 ModernaTX, Inc. $3,208.53 08/23/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002371
Principal investigator 1 Organon LLC $89,568.90 08/23/2023 Non-covered Recipient Entity
Velocity Clinical Research Inc.
OG-8175A-023 No dispute reported 06/30/2026 1016119099
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 08/22/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006243569
Principal investigator 1 GlaxoSmithKline, LLC. $4,750.00 08/16/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006243563
Principal investigator 1 ModernaTX, Inc. $535.20 08/16/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040214621
Principal investigator 1 ModernaTX, Inc. $1,151.02 08/16/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002129
Principal investigator 1 ModernaTX, Inc. $955.50 08/11/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040214565
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 08/08/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006243545
Principal investigator 1 Janssen Pharmaceuticals, Inc $7,938.00 08/02/2023 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094507
Principal investigator 1 ModernaTX, Inc. $1,506.70 08/02/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040213667
Principal investigator 1 ModernaTX, Inc. $432.25 07/28/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040213517
Principal investigator 1 ModernaTX, Inc. $18.52 07/26/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040213469
Principal investigator 1 ModernaTX, Inc. $3,000.00 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1040204171
Principal investigator 1 ModernaTX, Inc. $550.00 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1040206637
Principal investigator 1 ModernaTX, Inc. $3,185.00 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040213409
Principal investigator 1 ModernaTX, Inc. $11,016.85 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040213425
Principal investigator 1 ModernaTX, Inc. $500.00 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1040213791
Principal investigator 1 ModernaTX, Inc. $2,190.00 07/19/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1040223369
Principal investigator 1 PFIZER INC. $6,111.60 07/14/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045910949
Principal investigator 1 GlaxoSmithKline, LLC. $1,745.37 07/13/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE 3, OPEN-LABEL, RANDOMIZED, CONTROLLED, MULTI COUNTRY STUDY TO No dispute reported 06/30/2026 1127789724
Principal investigator 1 Janssen Pharmaceuticals, Inc $2,870.00 07/12/2023 Non-covered Recipient Entity
Velocity Clinic Rsrch
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094505
Principal investigator 1 PFIZER INC. $3,049.20 07/11/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045906561
Principal investigator 1 ModernaTX, Inc. $455.00 07/07/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040212281
Principal investigator 1 ModernaTX, Inc. $23,308.67 07/05/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040212209
Principal investigator 1 GlaxoSmithKline, LLC. $9,000.00 06/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789708
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 06/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789710
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 06/27/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789720
Principal investigator 1 ModernaTX, Inc. $550.00 06/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040206561
Principal investigator 1 ModernaTX, Inc. $6,290.00 06/23/2023 Non-covered Recipient Entity
ClinEdge, LLC - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1040223251
Principal investigator 1 PFIZER INC. $2,500.00 06/16/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045915065
Principal investigator 1 PFIZER INC. $33,987.60 06/14/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045904445
Principal investigator 1 ModernaTX, Inc. $938.60 06/07/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002121
Principal investigator 1 PFIZER INC. $3,775.20 06/03/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045908983
Principal investigator 1 PFIZER INC. $219.38 06/03/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1046497441
Principal investigator 1 Janssen Pharmaceuticals, Inc $3,750.00 05/24/2023 Non-covered Recipient Entity
Velocity Clinic Research, Inc.
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094843
Principal investigator 1 PFIZER INC. $4,936.80 05/19/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045918735
Principal investigator 1 GlaxoSmithKline, LLC. $1,654.29 05/17/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 1006243539
Principal investigator 1 GlaxoSmithKline, LLC. $3,065.04 05/17/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006243575
Principal investigator 1 ModernaTX, Inc. $308.75 05/03/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002115
Principal investigator 1 ModernaTX, Inc. $6,088.55 05/01/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002099
Principal investigator 1 PFIZER INC. $1,452.00 04/27/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045917621
Principal investigator 1 PFIZER INC. $1,417.50 04/22/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1046473001
Principal investigator 1 GlaxoSmithKline, LLC. $6,084.54 04/11/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789718
Principal investigator 1 GlaxoSmithKline, LLC. $6,084.54 04/11/2023 Non-covered Recipient Entity
VELOCITY CLINICAL RESEARCH INC
A NON-RANDOMIZED, OPEN LABEL, MULTI-COUNTRY, COHORT STUDY TO DESCRIBE No dispute reported 06/30/2026 1127789722
Principal investigator 1 PFIZER INC. $6,534.00 03/31/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045919149
Principal investigator 1 PFIZER INC. $5,808.00 03/30/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045916959
Principal investigator 1 PFIZER INC. $3,240.00 03/25/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1046457227
Principal investigator 1 ModernaTX, Inc. $3,001.05 03/24/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002109
Principal investigator 1 PFIZER INC. $10,018.80 03/04/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045917949
Principal investigator 1 Janssen Pharmaceuticals, Inc $1,000.00 03/03/2023 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094053
Principal investigator 1 ModernaTX, Inc. $2,156.38 02/24/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002085
Principal investigator 1 PFIZER INC. $8,857.20 02/24/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045903169
Principal investigator 1 Janssen Pharmaceuticals, Inc $13,613.00 02/23/2023 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094055
Principal investigator 1 ModernaTX, Inc. $5,140.52 02/22/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002079
Principal investigator 1 ModernaTX, Inc. $2,684.82 02/10/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002073
Principal investigator 1 PFIZER INC. $23,812.80 02/09/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIAL VIRUS RSV PREFUSION F SUBUNIT VACCINE IN INFANTS BORN TO WOMEN VACCINATED DURING PREGNANCY No dispute reported 06/30/2026 1045919297
Principal investigator 1 ModernaTX, Inc. $455.00 02/08/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002067
Principal investigator 1 PFIZER INC. $11,260.36 02/04/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 12 RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A MULTIVALENT GROUP B STREPTOCOCCUS VACCINE IN HEALTHY NONPREGNANT WOMEN AND PREGNANT WOMEN 18 TO 40 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1046470785
Principal investigator 1 ModernaTX, Inc. $669.99 02/01/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2a, randomized, stratified, observer-blind study to evaluate the immunogenicity and safety of mRNA-1283 vaccine boosters for SARS-CoV-2 No dispute reported 06/30/2026 1042002093
Principal investigator 1 ModernaTX, Inc. $5,061.88 01/27/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002055
Principal investigator 1 ModernaTX, Inc. $550.00 01/27/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002061
Principal investigator 1 ModernaTX, Inc. $2,190.00 01/27/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002365
Principal investigator 1 PFIZER INC. $54,401.12 01/27/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 2B RANDOMIZED PLACEBOCONTROLLED OBSERVERBLINDED TRIAL TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS RSV VACCINE IN PREGNANT WOMEN 18 THROUGH 49 YEARS OF AGE AND THEIR INFANTS No dispute reported 06/30/2026 1046547053
Principal investigator 1 GlaxoSmithKline, LLC. $386.10 01/25/2023 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 1006243525
Principal investigator 1 Janssen Pharmaceuticals, Inc $5,510.00 01/25/2023 Non-covered Recipient Entity
Medpharmics
A Study of an Adenovirus Serotype 26 Prefusion Conformation stabilized F Protein Ad26. RSV. preF Based Respiratory Syncytial Virus RSV Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older No dispute reported 06/30/2026 986094057
Principal investigator 1 ModernaTX, Inc. $11,596.65 01/25/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002047
Principal investigator 1 ModernaTX, Inc. $1,840.15 01/20/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 3, Randomized, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age No dispute reported 06/30/2026 1042002103
Principal investigator 1 GlaxoSmithKline, LLC. $193.05 01/18/2023 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 1006243531
Principal investigator 1 ModernaTX, Inc. $1,352.33 01/18/2023 Non-covered Recipient Entity
Velocity Clinical Research - Phoenix - PPDS
A Phase 2/3, Two-Part, Open-Label, Dose Escalation, Age De-escalation and Randomized, Observer Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA 1273 SARS-CoV-2 Vaccine in Health No dispute reported 06/30/2026 1042002041
Principal investigator 1 GlaxoSmithKline, LLC. $4,969.80 01/11/2023 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVA No dispute reported 06/30/2026 1006243315
Principal investigator 1 GlaxoSmithKline, LLC. $3,668.94 01/11/2023 Non-covered Recipient Entity
MEDPHARMICS LLC
A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTI-COUNTR No dispute reported 06/30/2026 1006243321
Principal investigator 1 PFIZER INC. $15,700.00 01/06/2023 Non-covered Recipient Entity
MedPharmics LLC
A PHASE 23 PLACEBOCONTROLLED RANDOMIZED OBSERVERBLIND STUDY TO EVALUATE THE SAFETY TOLERABILITY AND IMMUNOGENICITY OF A SARSCOV2 RNA VACCINE CANDIDATE BNT162B2 AGAINST COVID19 IN HEALTHY PREGNANT WOMEN 18 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1046371913